You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Low Cost and Rapid DNA-Based Biometric Device

    SBC: NetBio, Inc.            Topic: HSB091001

    Sensitive site exploitation activities are focused on collecting forensic evidence left behind by persons involved in terrorist or other illegal activity, and the biological evidence recovered is often referred to as"touch DNA samples". Touch samples include fingerprints, skin cells found on clothing (e.g. a shirt collar), and oral epithelial cells found on the opening of a soda can or the rim of ...

    SBIR Phase II 2011 Department of DefenseSpecial Operations Command
  2. Microfabricated Implantable Flowmeter for CSF Shunts Phase II

    SBC: VIVONICS INC            Topic: NINDS

    DESCRIPTION (provided by applicant): An implantable wireless flow sensor system has been under development that would enable measurement of the flow of cerebrospinal fluid (CSF) through the ventriculoperitoneal (VP) shunt, currently used to treat hydrocephalus patients. CSF flow is a key indicator of shunt function, and there is currently no way to measure it in situ, resulting in the absence ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Type III Secretion Inhibitors for Anti-Infective Therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Pseudomonas aeruginosa infection is the leading cause of hospital-acquired pneumonia in patients undergoing mechanical ventilation. Current antibiotic treatments exhibit failure rates as high as 18%, even when the organism is susceptible to the antibiotic being administered. The goal of this project is to address this critical medical need by identifying specif ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Regulatory Advancement of HXe as a Diagnostic MRI Contrast Agent

    SBC: XEMED LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): New therapies are in development for COPD (endobronchial valves/stents/glue) and asthma (endobronchial thermal ablation). Hyperpolarized xenon-129 (HXe) MRI, a noninvasive method to assess regional lung structure and function, may prove critical in the guidance of these regional treatments. In our prior work we developed an innovative approach to xenon polariza ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Diagnostic Sequencing System for HIV Resistance Testing

    SBC: INTELLIGENT BIO-SYSTEMS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): As of 2008 the CDC estimated that there were approximately 1.1 million persons in the U.S. infected with HIV- 1 and about 56,000 new cases are diagnosed each year. During the mid-to-late 1990s, advances in treatment slowed the progression of HIV to AIDS and related deaths. Unfortunately, the treatment often leads to the emergence of drug resistant mutants of HI ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid sensitive low-cost test for resistant microbes causing hospital infections

    SBC: FIRST LIGHT BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): We propose to develop a novel automated platform to enable rapid, sensitive, user-friendly, and cost-effective screening for the antibiotic resistant bacteria that frequently cause serious healthcare associated infections. Every year, about 100,000 deaths result from 2 million serious healthcare associated infections at an estimated cost of 35B. About 20,000 f ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical Development of a Novel and Powerful Immunotherapeutic

    SBC: IMMURX LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): ImmuRx is developing a novel and potent immunotherapeutic product to stimulate the immune system. This will significantly increase the efficacy of existing and new therapeutic vaccines for the treatment of cancers suchas melanoma, lymphoma and lung cancer and for chronic infectious diseases such as Hepatitis C. The barrier to the induction of protective, thera ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Confirmatory Immunoblot Test for Chagas' Disease

    SBC: IMMUNETICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Chagas' Disease is a vector-borne parasitic infection of humans with Trypanosoma cruzi, which has recently been identified as an emerging and significant threat to transfusion safety and the blood supply. It is a chronic and potentially fatal condition which affects over 10 million people living in tropical regions of the Americas, is endemic in 21 countri ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Alzheimer's Disease Therapeutic

    SBC: APHIOS CORPORATION            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's Disease (AD) is a significant neurological disorder that afflicts more than 4.5 million Americans and more than 10 million people worldwide. The lack of a cure for AD will result in a demand for better and safer AD drugs. All of the drugs on the market today have serious side effects. Recently, researchers at The Blanchette Rockefeller Neurosci ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  10. High Throughput, Label-Fee Molecular Interaction Platform for Membrane Protein

    SBC: MOLECULAR SENSING, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Molecular interactions form the basis of healthy metabolism as well as the manifestation of disease, and comprise the very foundation of drug treatment. Tools available to study molecular interactions in their nascent environment and physiological concentrations without chemical modification, such as surface immobilization or labeling, are limited. Current labe ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government